Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 3/20 | 0.76 |
| ▸ | MAOB | P27338 | 2/20 | 0.76 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.76 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.76 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.76 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.76 |
| ▸ | BACE1 | P56817 | 9/20 | 0.74 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.68 |
| ▸ | MAOA | P21397 | 1/20 | 0.68 |
| ▸ | IAPP | P10997 | 3/20 | 0.68 |
| ▸ | LCK | P06239 | 1/20 | 0.67 |
| ▸ | NQO2 | P16083 | 1/20 | 0.67 |
| ▸ | MMP1 | P03956 | 2/20 | 0.65 |
| ▸ | MMP2 | P08253 | 2/20 | 0.65 |
| ▸ | MMP9 | P14780 | 2/20 | 0.65 |
| ▸ | XDH | P47989 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3671201 | 1.00 | AKR1B1 (0.76) | AKR1B1MAOBAKR1B10PTGS2GLO1 | |
| SCHEMBL29565303 | 1.00 | AKR1B1 (0.76) | AKR1B1MAOBAKR1B10PTGS2GLO1 | |
| Didemethylcurcumin SCHEMBL613666 | 0.93 | IAPP (0.77) | AKR1B1MAOBAKR1B10PTGS2GLO1 | |
| Didemethylcurcumin SCHEMBL613667 | 0.93 | IAPP (0.77) | AKR1B1MAOBAKR1B10PTGS2GLO1 | |
| Bisdemethoxycurcumin SCHEMBL428638 | 0.87 | AKR1B1 (1.00) | AKR1B1MAOBAKR1B10PTGS2GLO1 | |
| Bisdemethoxycurcumin SCHEMBL2574140 | 0.87 | AKR1B1 (1.00) | AKR1B1MAOBAKR1B10PTGS2GLO1 | |
| SCHEMBL10021657 | 0.86 | CYP2C9 (0.74) | AKR1B1AKR1B10BACE1IAPPLCK | |
| SCHEMBL3214875 | 0.85 | AKR1B1 (0.69) | AKR1B1MAOBAKR1B10PTGS2GLO1 | |
| SCHEMBL3221692 | 0.85 | BACE1 (1.00) | AKR1B1MAOBAKR1B10PTGS2GLO1 | |
| SCHEMBL3214862 | 0.85 | AKR1B1 (0.69) | AKR1B1MAOBAKR1B10PTGS2GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023219526-A1 | MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT | PROKIN MILAN (RS) | 2023-11-16 | — | — | WO | claimed |
| US-20130102498-A1 | COMPOSITIONS AND METHODS FOR DETECTING AMYLOID-BETA-DEGRADING ENZYME ACTIVITY | ACADEMIA SINICA (TW) | 2013-04-25 | — | — | US | claimed |
| WO-2023219526-A1 | MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT | PROKIN MILAN (RS) | 2023-11-16 | — | — | WO | disclosed |
| US-20220305401-A1 | EUTECTIC EXTRACTION OF SOLIDS | GIVAUDAN SA (CH) | 2022-09-29 | — | — | US | disclosed |
| US-20150232642-A1 | POLYMERIC NANOPARTICLES COMPRISING TURMERIC | XEROX CORPORATION (US) | 2015-08-20 | — | — | US | disclosed |
| US-9074238-B2 | Methods for enhancing neprilysin activity and degrading amyloid-beta peptides and oligomers in a subject with Alzheimer's disease | ACADEMIA SINICA (TW) | 2015-07-07 | — | — | US | disclosed |
| EP-1933625-B1 | PROCESS FOR PRODUCING ENRICHED FRACTIONS OF TETRAHYDROXYCURCUMIN AND TETRAHYDROTETRAHYDROXY-CURCUMIN FROM THE EXTRACTS OF CURCUMA LONGA | LAILA NUTRACEUTICALS (IN) | 2014-07-09 | — | — | EP | disclosed |
| US-8680143-B2 | Orally active curcuminoid compounds | LAILA PHARMACEUTICALS PVT. LTD. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680143-B2 | Orally active curcuminoid compounds | LAILA PHARMACEUTICALS PVT. LTD. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8568802-B2 | Process for producing enriched fractions of tetrahydroxycurcumin and tetrahydrotetrahydroxy-curcumin from the extracts of Curcuma longa | LAILA IMPEX (US) | 2013-10-29 | — | — | US | disclosed |
| US-8568802-B2 | Process for producing enriched fractions of tetrahydroxycurcumin and tetrahydrotetrahydroxy-curcumin from the extracts of Curcuma longa | LAILA IMPEX (US) | 2013-10-29 | — | — | US | disclosed |
| US-20100227828-A1 | NEW SYNERGISTIC PHYTOCHEMICAL COMPOSITION FOR THE TREATMENT OF OBESITY | LAILA NUTRACEUTICALS (IN) | 2010-09-09 | — | — | US | disclosed |
| US-20100227828-A1 | NEW SYNERGISTIC PHYTOCHEMICAL COMPOSITION FOR THE TREATMENT OF OBESITY | LAILA NUTRACEUTICALS (IN) | 2010-09-09 | — | — | US | disclosed |
| US-20100168248-A1 | PROCESS FOR PRODUCING ENRICHED FRACTIONS OF TETRAHYDROXYCURCUMIN AND TETRAHYDROTETRAHDROXY-CURCUMIN FROM THE EXTRACTS OF CURCUMA LONGA | LAILA IMPEX (IN) | 2010-07-01 | — | — | US | disclosed |
| US-20100168248-A1 | PROCESS FOR PRODUCING ENRICHED FRACTIONS OF TETRAHYDROXYCURCUMIN AND TETRAHYDROTETRAHDROXY-CURCUMIN FROM THE EXTRACTS OF CURCUMA LONGA | LAILA IMPEX (IN) | 2010-07-01 | — | — | US | disclosed |
| US-20100168248-A1 | PROCESS FOR PRODUCING ENRICHED FRACTIONS OF TETRAHYDROXYCURCUMIN AND TETRAHYDROTETRAHDROXY-CURCUMIN FROM THE EXTRACTS OF CURCUMA LONGA | LAILA IMPEX (IN) | 2010-07-01 | — | — | US | disclosed |
| US-20100098676-A1 | SYNERGISTIC ANTI-INFLAMMATORY AND ANTIOXIDANT DIETARY SUPPLEMENT COMPOSITIONS | LAILA IMPEX (IN) | 2010-04-22 | — | — | US | disclosed |
| US-20100098676-A1 | SYNERGISTIC ANTI-INFLAMMATORY AND ANTIOXIDANT DIETARY SUPPLEMENT COMPOSITIONS | LAILA IMPEX (IN) | 2010-04-22 | — | — | US | disclosed |
| WO-2010004579-A2 | ORALLY ACTIVE CURCUMINOID COMPOUNDS | LAILA PHARMACEUTICALS PVT. LTD. (IN) | 2010-01-14 | — | — | WO | disclosed |
| WO-2008120220-A1 | SYNERGISTIC ANTI-INFLAMMATORY AND ANTIOXIDANT DIETARY SUPPLEMENT COMPOSITIONS | GOKARAJU GANGA RAJU (IN) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168248-A1 | PROCESS FOR PRODUCING ENRICHED FRACTIONS OF TETRAHYDROXYCURCUMIN AND TETRAHYDROTETRAHDROXY-CURCUMIN FROM THE EXTRACTS OF CURCUMA LONGA | HMOX1, HMOX2, HPD | AKR1B1 1470/4885MAOB 1237/4885AKR1B10 1368/4885 |
| US-20100098676-A1 | SYNERGISTIC ANTI-INFLAMMATORY AND ANTIOXIDANT DIETARY SUPPLEMENT COMPOSITIONS | TPSB2, MMP13, MMP11 | AKR1B1 1220/4885MAOB 1573/4885AKR1B10 2000/4885 |
| US-20100227828-A1 | NEW SYNERGISTIC PHYTOCHEMICAL COMPOSITION FOR THE TREATMENT OF OBESITY | BMI1, FABP4, LIPC | AKR1B1 1828/4885MAOB 895/4885AKR1B10 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.